Equities research analysts at StockNews.com assumed coverage on shares of Kamada (NASDAQ:KMDA – Get Free Report) in a note issued to investors on Thursday. The firm set a “buy” rating on the biotechnology company’s stock.
Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Kamada in a research report on Thursday, May 9th.
Read Our Latest Analysis on Kamada
Kamada Stock Down 1.7 %
Kamada (NASDAQ:KMDA – Get Free Report) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The company had revenue of $37.74 million during the quarter, compared to the consensus estimate of $38.01 million. Kamada had a return on equity of 5.50% and a net margin of 8.33%. As a group, analysts expect that Kamada will post 0.26 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in KMDA. EWA LLC purchased a new stake in shares of Kamada in the 4th quarter worth $68,000. Y.D. More Investments Ltd increased its position in Kamada by 107.1% in the fourth quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after buying an additional 15,000 shares in the last quarter. Aristides Capital LLC raised its stake in shares of Kamada by 41.6% in the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after buying an additional 16,635 shares during the period. Calton & Associates Inc. purchased a new position in shares of Kamada during the 4th quarter valued at about $111,000. Finally, Vanguard Group Inc. grew its stake in shares of Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after acquiring an additional 100,800 shares during the period. 20.38% of the stock is currently owned by institutional investors.
Kamada Company Profile
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Featured Articles
- Five stocks we like better than Kamada
- Market Cap Calculator: How to Calculate Market Cap
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Trading Stocks: RSI and Why it’s Useful
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.